MedElevator Войти в исследования
← Поиск публикаций

DOI 10.9740/mhc.2023.10.239

Медицинская библиотека · The mental health clinician · 2023

Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report.

Baldwin Kaitlyn, Wanson Annabelle, Gilecki Lee-Anne, Dalton Courtney, Peters Evyn, Halpape Katelyn

Клинический случайСтатьяПеревод в очереди

Аннотация

BACKGROUND

Neuropsychiatric symptoms associated with long COVID are a growing concern. A proposed pathophysiology is increased inflammatory mediators. There is evidence that typical serotonergic antidepressants have limited efficacy in the presence of inflammation. Although ketamine has shown promise in MDD, there is limited evidence supporting the use of ketamine to treat depressive symptoms associated with long COVID.

CASE REPORT: This case took place on an inpatient psychiatry unit in a Canadian hospital. The patient was admitted with a 10-month history of worsening depression and suicidality following infection with COVID-19. Depressive symptoms and suicidal ideation were assessed throughout treatment using the Montgomery-Asberg Depression Rating Scale (MADRS). Written informed consent was obtained prior to data collection. This patient received 4 doses of intranasal ketamine which resulted in rapid improvement of depressive symptoms and complete resolution of suicidality with no major adverse events.

DISCUSSION: There is evidence to support long COVID symptoms result from dysregulated inflammatory processes. The presence of inflammation in patients with MDD has correlated to poor outcomes with first-line antidepressants. It has been demonstrated that IV ketamine is associated with decreased inflammatory mediators and proportional decrease in depressive symptoms.

CONCLUSIONS

Intranasal ketamine in this case was effective at treating depressive symptoms and suicidal ideation associated with long COVID. This is consistent with available data that demonstrates ketamine's efficacy in reducing inflammatory mediators associated with neuropsychiatric symptoms. Therefore, ketamine may be a potential therapeutic option to treat long COVID and persistent depressive symptoms.

Для цитирования: Baldwin Kaitlyn, Wanson Annabelle, Gilecki Lee-Anne, Dalton Courtney, Peters Evyn, Halpape Katelyn. Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report.. The mental health clinician. 2023. DOI: 10.9740/mhc.2023.10.239.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.